 |
Vol.43 No.7 contents | Japanese/English |
 | Full Text of PDF (124K) Article in Japanese |
- -
Combination Chemotherapy With Nedaplatin and Docetaxel as a Treatment of Squamous Cell Lung Cancers
Shozo Fujino11Department of Thoracic Surgery
Objective. To evaluate the efficacy and safety of the nedaplatin (CDGP) -docetaxel (TXT) combination in patients with squamous cell lung cancer. Patients and methods. Thirty-two patients with histologically confirmed squamous cell lung cancer were treated and evaluated (2 with stage IIB, 11 with stage IIIA, 7 with stage IIIB, 9 with stage IV and 3 recurrent cases). There were 30 males and 2 females and their mean age was 65.3 (42-89). Five patients received previous chemotherapy and 10 received concurrent or sequential radiotherapy. Patients received CDGP (80-140 mg/body) and TXT (80-140 mg/body) on day 1 with 1,000 ml hydration. Treatment was repeated every four weeks. Results. Fifty eight courses were performed for 32 patients. The mean dosage per course of CDGP and TXT were 66.1 mg/m2 (49.1-82.4) and 65.8 mg/m2 (49.1-82.4) respectively. Two complete and 17 partial responses were observed (overall response rate (OR): 59.4%). The OR was 57.7% and 40.0% in patients without radiotherapy and with previous chemotherapy respectively. Thirteen patients were dead and 19 were alive at 10.7 months mean follow up time. The 1, 2 and three-year survival rate were 67.2%, 28.5%, 28.5% for all 32 cases and 62.6%, 11.9%, 11.9% in chemotherapy alone cases. Grade 3/4 leucocytopenia and thrombocytopenia occurred in 39 courses and 2 courses respectively. Grade 3/4 nausea/vomiting was observed in only one patient and there was no grade 3 nephrotoxicity. There was no treatment-related death. Conclusions. The nedaplatin-docetaxel combination is an active and safe regimen in squamous cell lung cancers.
key words: Nedaplatin, Cisplatin derivative, Docetaxel, Squamous cell carcinoma
JJLC 43 (7): 900-905, 2003
